ERBB2 gene amplifications that were present in 5.6% of acquired RET+ patients were also associated with poor prognosis in NSCLC patients (median: 5.6 vs. 10.0 months, P = 0.041, Fig. 4d). Here, RET is linked to non-small cell lung carcinoma.